CGEM News and Press, Cullinan Oncology Inc. From 09/22/22

Summary Shares have fallen by 40% since 2021 IPO was priced. I like management's unique approach of focusing on high-impact targets first and then determining the optimal modality after. Robust cash position (runway through 2026) allows them to prosecute clinical programs more...

Summary Cullinan Oncology's total cash and short-term investment is $611 million, up 94% from the previous quarter. The company's portfolio consists of eight product candidates that can significantly improve the quality of life of patients suffering from various types of cancer. ...

CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today announced that Company management wi...

Cullinan Oncology ( NASDAQ: CGEM ) granted stock options to buy 125.7K common shares to three employees as an inducement material for entering into employment with the company. The stock options have an exercise price of $13.02, which is equal to the closing price of C...

CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapeutic candidates across multiple modalities for patients with cancer...

Seth Klarman’s 13F portfolio value decreased from $9.30B to $6.77B this quarter. Baupost Group added Warner Bros. Discovery and Amazon while reducing Alphabet, Intel Corp., Nexstar Media, and Verint Systems. The portfolio continues to be heavily concentrated with the top th...

Cullinan Oncology press release ( NASDAQ: CGEM ): Q2 GAAP EPS of $3.77 misses by $1.65 . Cash and investments were $656 million For further details see: Cullinan Oncology GAAP EPS of $3.77 misses by $1.65

Completed agreement for strategic collaboration to jointly develop and commercialize CLN-081 with Taiho Pharmaceutical Presented updated Phase 1/2a data for CLN-081 at the 100mg BID dose showing median duration of response greater than 21 months and median progression-free survi...

CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today announced that its Chief Financial Of...

CAMBRIDGE, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today announced that its Chief Scientific Officer, P...